Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 10, 2008, Pages 982-988

  Patterson, M Kay ^a   Castellsague, Jordi ^b   Walker, Alexander M ^c  

^a i3 Drug Safety   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c World Health Information Science Consultants LLC   (United States)

Author keywords

COX 2 inhibitors; Epidemiology; NSAID; Peptic ulcer and bleeding

Indexed keywords

ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; STEROID; VALDECOXIB; WARFARIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ULCER PERFORATION; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; YOUNG ADULT;

EID: 57649165075     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1639     Document Type: Article

References (20)

1. Food and Drug Administration. COX-2 selective (includes bextra, celebrex, and vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). FDA center for drug evaluation and research. http://www.fda.gov/cder/drug/infopage/cox2/ [accessed March 2007].
2. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.
3. Gisbert JP, Gonzalez L, de Pedro A, et al. Helicobacter pylori and bleeding duodenal ulcer: prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 2001; 36: 717-724.
4. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-1899.
5. Langman MJ. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? Pharmacoepidemiol Drug Saf 2001; 10: 13-19.
6. Goldstein JL, Silverstein FE, Agarwal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-1690.
7. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019-1027.
8. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 284: 1247-1255.
9. Hrachovec JB, Mora M. Reporting of 6-month vs. 12-month data in a clinical trial of celecoxib. JAMA 2001; 286: 2398-2400.
10. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54: 320-326.
11. Singh G, Fort JG, Goldstein JL, et al. and SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119(3): 255-266.
12. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a cochrane collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5(7): 818-828.
13. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003; 115: 715-720.
14. International Society for Pharmacoepidemiology (ISPE). Guidelines for Good Pharmacoepidemiology Practices (GPP). http://www.pharmacoepi.org/ resources/guidelines_08027.cfm. [accessed 14 March 2007].
15. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 624.
16. Lanas A, Garcia-Rodriguez LA, ArroyoMT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55(12): 1731-1738.
17. Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs. non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 2007; 46(3): 435-438.
18. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331(7528): 1310-1316.
19. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: 268-275.
20. Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum 2006; 54: 3390-3398.